Q4 2022 13F Holders as of 31 Dec 2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
90,438,636
-
Number of holders
-
386
-
Total 13F shares, excl. options
-
55,494,852
-
Shares change
-
-1,231,395
-
Total reported value, excl. options
-
$2,255,613,450
-
Value change
-
-$74,822,214
-
Put/Call ratio
-
92%
-
Number of buys
-
156
-
Number of sells
-
193
-
Price
-
$40.65
Institutional Holders of CRISPR Therapeutics AG - Common Stock (CRSP) as of Q4 2022
As of 31 Dec 2022 CRISPR Therapeutics AG - Common Stock (CRSP) had 386 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 55,494,852 shares of stock of the company.
Largest 10 holders included ARK Investment Management LLC, Capital International Investors, Sumitomo Mitsui Trust Holdings, Inc., Nikko Asset Management Americas, Inc., T. Rowe Price Investment Management, Inc., BlackRock Inc., FMR LLC, STATE STREET CORP, NEA Management Company, LLC, and VANGUARD GROUP INC.
This table shows 386 institutional shareholders of the security as of 31 Dec 2022.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.